Your session is about to expire
← Back to Search
HIPEC for Peritoneal Cancer
Study Summary
This trial is testing if different chemotherapy drugs used during HIPEC can improve outcomes for people with peritoneal carcinomatosis.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am HIV-positive with an undetectable viral load and on antiretroviral therapy.My cancer, originating from the appendix, colon, ovary, or peritoneum, has spread within the abdomen.My cancer's growth can be measured or evaluated.I am fully active and can carry on all pre-disease activities without restriction.My blood counts and liver/kidney functions are within normal ranges.I haven't had cancer treatment in the last 4 weeks.I am allergic to medications that contain platinum.I do not have any serious illnesses or social situations that would stop me from following the study's requirements.My doctor believes I can have all visible cancer removed, with a PCI score of 30 or less.I have not had major surgery in the last 12 weeks.I am 18 years old or older.My cancer has spread beyond my abdomen from my appendix, colon, ovary, or the lining of my abdomen.I have a genetic deficiency related to my appendiceal or colorectal cancer.I am not pregnant or breastfeeding as the treatment involves major surgery and drugs that could harm a baby.
- Group 1: 4/ HIPEC: Cisplatin, Mitomycin C Randomized treatment assignme
- Group 2: 3/ HIPEC: Cisplatin, Doxorubicin Randomized treatment assignme
- Group 3: 1/ HIPEC: Oxaliplatin Randomized treatment assignment
- Group 4: 2/ HIPEC: Mitomycin C Randomized treatment assignment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are involved in the experiment?
"Affirmative. Clinicaltrials.gov reveals that this study, first posted on October 19th 2021, is recruiting patients at present. A total of 60 subjects need to be recruited from a single medical centre for the trial's success."
Is this clinical trial open for enrolment?
"Affirmative. Clinicaltrials.gov details that this study, which was initially posted on October 19th 2021 is now recruiting participants. Approximately 60 patients are to be recruited from one medical centre."
Is this experiment novel in its approach?
"A total of 2346 trials have been conducted since the inception of Heated Intraperitonial Chemotherapy studies in 1997. As it stands, 1436 are active and sprawled across 78 nations with 3902 cities involved. Alfacell initially spearheaded a Phase 3 study which included 300 participants."
What ailments are addressed by the application of Heated Intraperitonial Chemotherapy?
"Heated Intraperitonial Chemotherapy is the main treatment approach used to manage neoplasms. This procedure can also reduce symptoms associated with colorectal neoplasms, actinic keratosis and acute lymphoblastic leukemia (ALL)."
Has heated intraperitoneal chemotherapy been previously evaluated in clinical studies?
"Currently, 1436 clinical trials are studying the potential benefits of Heated Intraperitonial Chemotherapy with 518 Phase 3 trials. Most of these studies originate out of Guangzhou, Guangdong yet there also exist 81016 other medical facilities conducting research on this topic."
Has the FDA granted permission for Heated Intraperitonial Chemotherapy?
"Limited clinical data confirms the safety of Heated Intraperitonial Chemotherapy, so it was assigned a rating of 1."
Share this study with friends
Copy Link
Messenger